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ABSTRACT 
The problem of ageing is experienced by all the countries. According to World Health statistics the life 
expectancy of Nepalese people has risen from 58.91 years to 67.86 years (1996 to 2015). Ageing is 
emerging issue in Nepal as well as global. Its tempo is expected to be unexpectedly fast as mortality 
continues to decline and life expectancy continues to increase. Ayurveda the science of life has observed 
ageing as a Jara avastha, which is a later phase of life, it is natural, inevitable phenomenon, in which 
maximum decline of bodily elements that may become as major cause of disability and functional 
dependency requiring services that affect many sectors of economy, health, security, income, housing, 
transportation etc. Jara chikitsa has been mentioned as one independent Anga in Ashtanga Ayurveda 
where Rasayana therapy is capable to impede the ageing process and to delay the degenerative process in 
the body. In this study we measured the effectiveness of Ashwagandha rasayana and Matra basti and 
compared with the Ashwagandha Rasayan only in Jara avastha. A total of thirty elderly patients were 
selected and divided in two groups A and B, given them either Ashwagandha Rasayana with Matra basti or 
Ashwagandha rasayana in prescribed doses for 45 days. Changes in the subjective complaints, objective 
parameters of the patients and appearance of adverse events were also evaluated. Both the groups 
provided better results on the chief complaints But, comparison in between both the groups is 
insignificant, that may be due to small sample size. 
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INTRODUCTION 
 Though growing old is a part of life cycle, a strong 
group of above 60 years of age is building up to cause 
further challenge to the medical world. In Nepal the older 
population accounts for about 8.1 percent of the total 
population and a majority (over 6 out of 10) of them are in 
their sixties[1], elderly people are defined as those above 
60 years of age as per the WHO definition and they are 
addressed as Senior Citizens.[2] The Central Bureau of 
Statistics (CBS) of Nepal reported that the percentage of 
population aged 60 years and above increased from 5.0 % 
during 1952- 54, 5.8 % in 1991, 6.5% during 2001 and 
8.1% in 2011 accounting for an increase of nearly 2.46 
million.[3] Recently, worldwide population ageing have 
been considered one of the most important demographic 
phenomena. It is the product of clear decreases in birth 
and mortality rates and an increase in life expectancy, 
which is reflected in the socio-economical progress of 
countries. [4] The worldwide population aged 60 years and 
older will surpass from approximately 770 million in 2010 
to an estimated one billion in 2020, and 20.0% of these 
people will be concentrated in developing countries, Thus, 
it needs to be addressed and proper attention should be 
given to the elderly people.[5] 
 Geriatrics is a vast branch of medicine dealing 
exclusively with the problems of ageing and the diseases of 
elderly like, degenerative deficits, dementia, Parkinson’s 
disease, C.O.P.D, Insomnia etc. The World Health 
Organization (WHO) very appropriately declared the 
calendar year 1999 as the year of Elderly People – Senior 
Citizens, to focus on the growing problems of the ageing 
people. This offers an opportunity to gather the scattered 
matter spread over many Ayurvedic classics and other 
sources of information. 
 The problem is how to keep old people physically 
fit and how to make them useful to society. This calls for 
intensive research into the causes which leads to ageing. 
 Ayurveda the science of life has observed ageing 
as a graceful phenomenon. Old age and its health problems 
were of great concern even for Acharyas during Vedic 
period. That was the reason why Jara Chikitsa has been 
mentioned as one independent Anga in Ashtanga 
Ayurveda. It implies delaying the process of ageing, 
prevention and managing the problems of old age by using 
of Rasayana drugs. This Jara or Rasayana chikitsa has 
widely emphasized promoting, protecting and extending 
youthful state and thus curtailing ageing process. It is 
therapy which gives longevity, enhances memory and 
intellect, maintains good health and restores youth, 
complexion, body colour, voice. It also gives strength to the 
physical and to the sense and cognitive organs.[6] So, there 
is responsibility to come forward to take preventive 
measures and treatment aspects for the old age problem. 
 All the Rasayana drugs have properties like 
Medhya, Balya, Dhatupushtikara, Brumhaniya, Jivaniya, and 
Agnivardhaka etc. and also have proven pharmacological 
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actions, such as: Adaptogens, Antioxidant, Immuno-
stimulants, Antistress, Nootropics, Anabolics, Tonics and 
other geriatric properties. Thus, Rasayana formulations 
described in the classics have very good composition with 
maximum properties on demand. Ashwagandha rasayana 
and Matra basti is selected for the study because 
Ashwagandha (Withania somnifera) is explained as Tikta, 
Katu- kashaya rasayukta, Ushna veerya, Madhur vipaka it is 
Vata kapha shamaka, Sukrala, Balya, Rasayana like Jara 
vikara nashaka, Dhatu vardhaka etc.[7] Rasayana promotes 
digestion and metabolism, thereby proper production to 
Rasa dhatu and elimination of toxic metabolites is 
achieved, which in turn promote Dhatu poshana. Prabhava 
of Rasayana does the equilibrium of Tridosha, which is 
responsible to restore normal physical and mental 
activities in the same way Matrabasti is a very unique 
therapeutic procedure because of its preventive, health 
promotive, rejuvenative properties. It is applicable in all 
Vatavyadhis (neurological deficits). Matra basti is most 
indicated procedure in Vrudhas due to property of Balya, 
Vatahara and Agni Sandhukshana[8] By using Aswagandha 
rasayana and Matra basti the quality of life of elderly may 
be improved and ageing process may be delayed and can 
be postponed. So, the topic “A Comparative Clinical Study 
on ‘Jara’ With Respect to Ageing Process with 
Ashwagandha Rasayana and Matra Basti “was been 
undertaken for study. 
OBJECTIVE OF THE STUDY  
General Objectives 
 To find out a safe and effective intervention in the 
management of Jaraavastha, that could improve the 
quality of life in the elderly. 
Specific 
 To evaluate the effectiveness of Ashwagandha 
rasayana and Matra basti in improving quality of life 
in elderly persons. 
 To compare the effectiveness of both Ashwagandha 
rasayana and Matra basti in improving quality of life 
in elderly persons.  
MATERIALS AND METHODS 
Materials 
A. Drugs  
1. Group A - Ashwagandha churna 
2. Group B - Ashwagandha churna Mahanarayan tail, 
Shatapushpa churna and Saindhava lavana. 
Source of drugs - Ashwagandha churna and Mahanarayan 
tail are prepared as per classical references 
B. Thirty old age persons 
C. Instruments 
1. Syphagnomanometer 
2. Weighing machine 
3. Clinical thermometer 
4. Stop watch 
5. Glycerine syringe of 60 ML 
6. Catheter no 9. 
Sources 
 The literary sources of the study were collected 
from the classical texts of Ayurveda, published journals, 
modern texts, international editions and internet. The 
elderly persons were taken from OPD and IPD of TU 
Ayurveda Teaching Hospital, Kirtipur and Medical camps 
conducted by the institute. 
Sampling method 
 Minimum of 30 elderly persons were selected 
excluding drop outs. They were assigned into two groups 
consisting of 15 persons in each group viz., Group A and 
Group B. Statistical analysis were done on subjective 
parameters such as Agnimandhya, Malabadhata, Bala 
Kshaya, Grahana Kshaya, etc. and objective parameters 
such as Haemoglobin, Blood Pressure Etc. as mentioned in 
Ayurvedic and modern texts by ‘Student’s t-test’. 
Inclusive Criteria 
1) Elderly persons with classical symptoms of Jara such as 
Agnimandya, Bala Kshaya etc.  
2) Both sexes 
3) Age group in between 60 to 70yrs. 
Exclusive Criteria 
1) Elderly persons suffering from any other systemic 
disorders.  
2) Age above 70yrs.  
3) Senile psychosis.  
4) Elderly persons who are non co-operative. 
Study Design 
Group A 
Drug: Ashwagandha churna  
Dose: 5 gm B.D.  
Method: Oral administration  
Anupana: Sarkara added Sukhoshna dugdha  
Duration: 45 days  
Follow up: 15th Days 
Group B:  
Drug: Ashwagandha churna 5 gm BD with Sarkara added 
Sukhoshna Dugdha as Anupana and 60 ML of 
Mahanarayana tail Matra Basti. 
Investigations were done for both the groups before and 
after the treatment. 
Investigations 
 Hemoglobin. 
 Blood pressure 
 Weight  
ASSESMENT CRITERIA AND THEIR GRADINGS 
Subjective variables 
1) Agni mandya (Loss of Appetite) 
Grade 1: Normal Appetite.  
Grade 2: Diminished Appetite.  
Grade 3: Loss of interest in taking food. 
Grade 4: Aversion towards food. 
2) Mala baddhata (Constipation) 
Grade 1: No Constipation.  
Grade 2: Regular bowel movements, consistency hard, 
excessive straining, and prolonged defecation time. 
Grade 3: 3-5 Bowel movements per week, consistency 
hard. 
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Grade 4: Less than 3 Bowel movements per week, 
consistency hard. 
3) Balakshaya (Strength) 
 Grade 1: Normal strength.  
 Grade 2: Movement against some resistance only. 
 Grade 3: Movement against gravity only.  
 Grade 4: Movement with gravity eliminated only. 
 Grade 5: Palpable contraction or flicker.  
 Grade 6: No movement. 
4) Grahana kshaya (Loss of Grasping power) 
 Person was asked to withhold the cuff of 
sphygmomanometer in folding manner for maximum time 
at maximum mercury level.  
Grade 1: Can withhold more than 2min.  
Grade 2: Can withhold in between 61 sec. to 2 min.  
Grade 3: Can withhold in between 30-60 sec.  
Grade 4: Can withhold less than 30 sec. 
5) Nidra nasha (Insomnia)  
Grade 1: Adequate night sleep 6-8 hours.  
Grade 2: Inadequate night sleep 4-5 hours  
Grade 3: Inadequate night sleep 2-3 hours.  
Grade 4: Inadequate night sleep 1-2 hours or no 
sleep. 
6) Shwasa (Exertional Dyspnoea) 
Grade 1: Dyspnoea on unaccustomed exertion.  
Grade 2: Dyspnoea on accustomed Exertional work.  
Grade 3: Dyspnoea on routine activities like moving 
about in the house, going to toilet, having bath.  
Grade 4: Dyspnoea on rest. 
7) Sarva kriya cha asamartha (Functional impairment) 
Grade 1: Can perform routine work. No pain in joints 
of extremities.  
Grade 2: Mild pain and stiffness in joints, walks with 
limping but without support.  
Grade 3: Painful joints, walk without support, 
difficulty in performing daily routine.  
 Grade 4: Painful joints, Totally unable to perform 
daily routine. 
OBJECTIVE VARIABLES  
Systolic Blood Pressure  
Grade 1 100-130 mm of Hg.  
Grade 2 132-140 mm of Hg  
Grade 3 142 -150 mm of Hg  
Grade 4 152-160 mm of Hg 
Grade 5 above 160 
Diastolic Blood Pressure  
Grade 1 70-90 mm of Hg.  
Grade 2 92-100 mm of Hg.  
Grade 3 102-110 mm of Hg.  
Grade 4 above 110 mm of Hg.  
Weight  
Grade 1 - 70kg and above  
Grade 2 - 65.1-70kg.  
Grade 3 - 160.1 -65kg.  
Grade 4 - 55.1-60 kg  
Grade 5 - 50.1-55 kg  
Grade 6 - 45.1-50 kg. 
Grade 7 - 40.1-45 kg. 
Grade 8 - below 40 kg. 
Haemoglobin 
Grade 1 - 14gm% above  
Grade 2 - 12.1- 14 gm %  
Grade 3 - 10.1 -12 gm%  
Grade 4- 8.1-10 gm.% 
Grade 5 - less than 8 gm % 
Assessment on clinical improvement 
 Clinical improvement of the disease was based on 
improvement in the clinical finding and reduction on the 
severity of the symptoms of the disease grading for the 
clinical improvement for individual variables.  
Grading for the clinical improvement for individual 
variables. 
1. CD: Clinically deteriorated i.e. increase in severity score 
against the initial score.  
2. CS: Clinically stable, i.e. severity score remains as against 
the initial score.  
3. CI-1: encouraging i.e. I degree reduction in the severity 
score, against Initial score, i.e. reduction from mild-normal, 
Moderate-Mild and Severe- moderate.  
4. CI-2: Good i.e. 2 degree reduction in the severity score, 
against the score, i.e. reduction from moderate-normal, 
severe-mild.  
5. CI-3: excellent i.e. 3 degree reduction in the severity 
score, against the Initial Score, i.e. severe- normal.  
Grading for clinical improvement of overall severity:  
1. CD: Clinically deteriorated i.e. increase in severity score 
against the initial Score.  
2. CS: Clinically stable, i.e. severity score remains as against 
the initial score.  
3. CI-1: Clinically encouraging (1 – 6 degree reduction in 
severity score).  
4. CI-2: Clinically good i.e. (7 – 12 degree reduction in 
severity score). 
5. CI-3: Clinically excellent i.e. (More than 13 degree 
reduction in severity score). 
Statistical analysis 
 The data was collected from both groups before, 
after treatment and at the end of the follow up and 
statically analyzed by using ‘t’ test with the consultation of 
biostastician. 
OBSERVATION AND RESULTS 
 Total 30 persons were selected for the clinical 
study and they were randomly allocated to Group A, Group 
B respectively. The observations for the present study 
were done as. 
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Generalized Observations 
Table 1: Distribution of Patients Based on Agnimandya Before Treatment 
Agnimandya No. of Pt. from Group Total (n=30) Percentage 
A B 
Grad -4 0 0 0 0% 
Grade-3 3 3 6 20% 
Grade-2 12 12 24 80% 
Grade-1 0 0 0 0% 
Table 2: Distribution of Patients Based on Malabaddhata Before Treatment 
Malabaddhata No. of Pt. from Group Total (n=30) Percentage 
A B 
Grad -4 0 0 0 0% 
Grade-3 4 5 9 30% 
Grade-2 7 9 16 53.3% 
Grade-1 4 1 5 16.6% 
Table 3: Distribution of Patients Based on Balakshaya Before Treatment 
Balakshaya No. of Pt. from Group Total (n=30) Percentage 
A B 
Grad -4 0 0 0 0% 
Grade-3 1 0 1 3.3% 
Grade-2 13 15 28 93.3% 
Grade-1 1 0 1 3.3% 
Table 4: Distribution of Patients Based on Grahanakshaya Before Treatment 
Grahanakshaya No. of Pt. from Group Total (n=30) Percentage 
A B 
Grad -4 0 0 0 0 
Grade-3 2 2 4 13.3% 
Grade-2 11 11 22 73.3% 
Grade-1 2 2 4 13.3% 
Table 5: Distribution of Patients Based on Nidranasha Before Treatment 
Nidranasha No. of Pt. from Group Total (n=30) Percentage 
A B 
Grad -4 0 0 0 0 
Grade-3 1 2 3 10% 
Grade-2 14 11 25 83.3% 
Grade-1 0 2 2 6.6% 
Table 6: Distribution of Patients Based on Shwasa Before Treatment 
Grahanakshaya NO of Pt. from Group Total (n=30) Percentage 
A B 
Grad -4 0 0 0 0 
Grade-3 3 1 4 13.3% 
Grade-2 11 14 25 83.3% 
Grade-1 1 0 1 3.3% 
Table 7: Distribution of Patients Based on Sarvakriya Su Cha Asamartha Before Treatment 
Sarvakriya Su Cha 
Asamartha 
NO of Pt. from Group Total (n=30) Percentage 
A B 
Grad -4 0 0 0 0 
Grade-3 3 11 14 46.6% 
Grade-2 9 3 12 40% 
Grade-1 3 1 4 13.3% 
Table 8: Systolic Blood Pressure Wise Distributions 
S.No. Systolic B.P Group-A Group-B Total (n=30) Percentage 
1 100-120 mm of Hg 7 8 15 50% 
2 122-140 mm of Hg 5 4 9 30% 
3 142-160 mm of Hg 3 3 6 20% 
 
 Int. J. Ayur. Pharma Research, 2016;4(8):1-11  
 IJAPR | August 2016 | Volume 4 | Issue 8  5 
Table 9: Diastolic Blood Pressure Wise Distributions 
S.No. Diastolic B.P Group-A Group-B Total (n=30) Percentage 
1 70 - 90 mm of Hg 11 12 23 76.6% 
2 92 -100 mm of Hg 4 3 7 23.3% 
3 102 -110 mm of Hg 0 0 0 0% 
Table 10: Weight Wise Distributions 
S.No. Weight in K.G Group-A Group-B Total (n=30) Percentage 
1 Less than 40 Kg. 0 1 1 3.3% 
2 41-60 Kg. 6 7 13 43.3% 
3 61-80 Kg. 9 6 15 50% 
4 More than 80 Kg, 0 1 1 3.3% 
Table 11: Hemoglobin wise Distributions 
S.No. Hemoglobin Group-A Group- B Total (n=30) Percentage 
1 08-10 gm% 1 0 1 3.3% 
2 10.1 – 12 gm% 4 3 7 23.3% 
3 12.1 -14 gm% 6 10 16 53.3% 
4 14.1 – 16 gm% 4 2 6 20% 
Observations for Individual Group 
Group - A 
 All the patients were presenting with varied degree of Lakshanas. 
 The patients were given Ashwagandha churna 5 gm BD along with Sarkara added Sukhoshna dugdha as Anupana 
for 45 days. 
 Patients were comfortable during and end of treatment. 
 No adverse effects were seen. 
 All the patients came regularly for the post treatment follow up. 
Group- B 
 All the patients were presenting with varied degree of Lakshanas. 
 The patients were given Ashwagandha churna 5 gm BD with Sarkara added Sukhoshna dugdha as Anupana for 45 
days and Mahanarayan tail Matra basti for 8 days. 
 Patients were comfortable during and end of treatment. 
 No adverse effects were seen. 
 All the patients came regularly for the post treatment follow up. 
The Response of the Treatment for Individual Group (%) After Treatment 
Table 12: Subjective Parameters 
Variables Group CI-3 CI-2 CI-1 CS CD 
Agnimandhya A 0% 13.3% 86.6% 0% 0% 
B 0% 20% 80% 0% 0% 
Malabaddhata A 0% 0% 73.3% 26.6% 0% 
B 0% 33.3 60% 6.6% 0% 
Balakshaya A 0% 0% 93.3% 6.6% 0% 
B 0% 0% 100% 0% 0% 
Grahanakshaya A 0% 0% 80% 20% 0% 
B 0% 6.6% 73.3% 20% 0% 
Nidranasha A 0% 0% 100% 0% 0% 
B 0% 13.3% 73.3% 13.3% 0% 
Swasha A 0% 0% 80% 20% 0% 
B 0% 0% 93.3% 6.6% 0% 
Sarvakriya cha 
asamartha 
A 0% 0% 40% 60% 0% 
B 0% 13.3% 80% 6.6% 0% 
Table 13: Objective Parameters 
Variables Group CI-3 CI-2 CI-1 CS CD 
Systolic B.P A 0% 20% 6.6% 73.3% 0% 
B 0% 13.3% 13.3% 73.3% 0% 
Diastolic B.P A 0% 0% 26.6% 73,3% 0% 
B 0% 0% 20% 80% 0% 
Weight A 0% 0% 20% 80% 0% 
B 0% 0% 26.6% 73.3% 0% 
Hb% A 0% 0% 53.3% 40% 6.6% 
B 0% 6.6% 46.6% 46.6% 0% 
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Results Related for Individual Group After Treatment 
Group-A  
Excellent response- No patient showed excellent response after treatment.  
Good Response- In 13.3% patients of Agmimandhya and 20% of systolic pressure showed Good response after treatment 
Encouraging Response- 86.6% of Agnimandhya,73.3% of Mala baddhata, 93.3 % of Bala kshaya, 80% of Grahana kshaya, 
100% of Nidra nasha 80% of Shwasa, 40% of Sarva karya aswasamarth, 6.6% of systolic blood pressure, 26.6% of diastolic 
blood pressure, 20% of weight and 53.3% of Hb%, Showed encouraging response after treatment. Clinically stable - 
26.6% of Mala baddhata, 46.6% of Nidra nasha, 6.6% of Bala kshaya, 20% of Grahana kshaya, 20% of Shwasa, 60% of 
Sarva karya cha Aswasamarth, 73.3% 0f systolic blood pressure,73.3% of diastolic blood pressure, 80% of weight, 40% of 
Hb%, were clinically stable after treatment.  
Deteriorated – 6.66% persons of Hb% shown clinically deterioration at the end of the treatment. 
Group-B 
Excellent response- No patient showed excellent response after treatment.  
Good Response- In 20% patients of Agmimandhya, 33.3% of Malabadhata, 6.6% of Grahana kshaya, 13.3% of Sarvakriya 
cha asamartha, 13.3% of systolic pressure and 6.6% of Hb% showed Good response after the treatment. Encouraging 
Response- 80% of Agnimandhya, 60% of Mala baddhata, 100 % of Bala kshaya, 73.3% of Grahana kshaya, 73.3% of Nidra 
nasha 93.3% of Shwasa, 80% of Sarva karya cha Aswasamartha, 13.3% of systolic blood pressure, 20% of diastolic blood 
pressure, 26.6% of weight and 46.6% of Hb%, Showed clinically encouraging response after the treatment.  
Clinically stable - 6.6%of Mala baddhata, 20% of Grahana kshaya, 13.3% of Nidranasha 6.6% of Shwasa, 6.6% of Sarva 
karya cha Aswasamarth, 73.3% 0f systolic blood pressure, 80% of diastolic blood pressure, 73.3% of weight and 46.6% of 
Hb%, were clinically stable after treatment.  
Deteriorated – No patient showed clinically deterioration at the end of the treatment.  
Table 14: Percentage of patients from clinical improvement of overall severity after the Treatment 
Group CI-3 CI-2 CI-I CS CD 
A 0% 33.3% 66.6% 0% 0% 
B 0% 100% 0% 0% 0% 
The study indicates that 33% patients show clinically good and 66.6% patients clinically encouraging response from Group 
A where 100% patients show clinically good response. The patients from any group do not show excellent response or 
clinically stable or clinically deteriorated response after the treatment. 
 
   Figure - 1 showing the result of Group A Figure- 1.1 showing the result of Group-B 
after Treatment after treatment 
Table 15: Showing the Statistical Results of Group - A Paired Sample Test 
Variables before and 
after treatment 
Paired Differences t Df Sig.(2 
tailed) Mean Std. 
Deviatio
n 
Std. 
Error 
mean 
95% Confidence interval 
of Difference 
Lower Upper 
Pair 1 AgB - AgA 1.3333 .35187 .09085 .93848 1.32819 12.475 14 .000 
Pair 2 MaB - MaA .73333 .45774 .11819 .47985 .98682 6.205 14 .000 
Pair 3 BaB - BaB .93333 .25820 .06667 .79035 1.07632 14.000 14 .000 
Pair 4 GrB - GrA .80000 .41404 .10690 .57071 1.02920 7.483 14 .000 
Pair 6 SwB - SwB .80000 .41404 .10690 .57071 1.02920 7.483 14 .000 
Pair 7 SKB - SKA .40000 .50709 .13093 .11918 .68082 3.055 14 .009 
Pair 8 SyB - SyA .46667 .83381 .21529 .00492 .92841 2.168 14 .048 
Pair 9 DyB - DyA .26667 .45774 .11819 .01318 .52015 2.256 14 .041 
Pair 10 WtB - WtA .20000 .41404 .10690 .02929 .42929 1.871 14 .082 
Pair 11 HgB - HgA .46667 .63994 .16523 .11228 .82105 2.824 14 .014 
Group-A
Exellence
Good
Encouraging 
Stable
Deterioted
Group-B
Exellent
Good
Encouraging
Stable
Deterioated
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NB: The correlation and t test of Nidranasha (Pair 5- NiB-NiA) cannot be calculated because the standard error of the 
difference of the parameter is 0 
Table 16: Showing The Statistical Results Of Group - B Paired Sample Test 
Variables before and 
after treatment 
Paired Differences t Df Sig.(2 
tailed) Mean Std. 
Deviation 
Std. 
Error 
mean 
95% Confidence interval 
of Difference 
Lower Upper 
Pair 1 AgB - AgA 1.20000 .41404 .10690 .97071 1.42929 11.225 14 .000 
Pair 2 MaB - MaA 1.26667 .59362 .15327 .93793 1.59540 8.264 14 .000 
Pair 4 GrB - GrA .86667 .51640 .13333 .58070 1.15264 6.500 14 .000 
Pair 5 NiB - NiA 1.00000 .53452 .13801 .70399 1.29601 7.246 14 .000 
Pair 6 SwB - SwB .93333 .25820 .06667 .79035 1.07632 14.000 14 .000 
Pair 7 SKB - SKA 1.06667 .45774 .11819 .81318 1.32015 9.025 14 .000 
Pair 8 SyB - SyA .40000 .73679 .19024 .00802 .80802 2.103 14 .054 
Pair 9 DyB - DyA .20000 .41404 .10690 .02929 .42929 1.871 14 .082 
Pair 10 WtB - WtA .26667 .45774 .11819 .01318 .52015 2.256 14 .041 
Pair 11 HgB - HgA .60000 .63246 .16330 .24976 .95024 3.674 14 .003 
NB: The correlation and t test of Balakshaya (Pair 3- BaB-BaA) cannot be calculated because the standard error of the 
difference of the parameter is 0 
NOTE - AgB - Agnimandha before treatment, AgA - Agnumandha after treatment, MaB - Malabaddhata before treatment, 
MaA - Malabaddhata after treatment, BaB - Balakshaya before treatment, BaA - Balakshaya after treatment, GrB - Grahana 
kshaya before Treatment, GrA - Grahana kshaya after treatment, NiB -Nidranasha before treatment, NiA -Nidranasha after 
treatment, SwB - Shwasa before treatment, SwA - Shwasa after treatment, SKB - Sarvakriya cha asamarthata before 
treatment, SKA - Sarvakriya cha asamarthata after treatment, SyB - Systolic blood pressure before treatment, SyA - Systolic 
blood pressure after treatment. DyB - Diastolic blood pressure before treatment, DyA -Diastolic blood pressure after 
treatment WtB - Weight before treatment, WtA - Weight after treatment, HgB Hemoglobin before treatment and HgA - 
Hemoglobin after treatment. 
Table 17: Showing the Statistical Results of Group - A after 15 days follow-up Paired Sample Test 
Variables before and 
after treatment 
Paired Differences t Df Sig.(2 
tailed) Mean Std. 
Deviation 
Std. 
Error 
mean 
95% Confidence interval 
of Difference 
Lower Upper 
Pair 1 AgB - AgF .60000 .50709 .13093 .31918 .88082 4.583 14 .000 
Pair 2 MaB - MaF .40000 .50709 .13093 .11918 .68082 3.055 14 .009 
Pair 3 BaB - BaF .13333 .35187 .09085 -.06152 .32819 1.468 14 .164 
Pair 4 GrB - GrF .20000 .41404 .10690 -.02929 .42929 1.871 14 .082 
Pair 5 NiB - NiF .60000 .50709 .13093 .31918 .88082 4.583 14 .000 
Pair 6 SwB - SwF .13333 .35187 .09085 -.06152 .32819 1.468 14 .164 
Pair 7 SKB - SKF .13333 .35187 .09085 -.06152 .32819 1.468 14 .164 
Pair 8 SyB - SyF .26667 .59362 .15327 -.06207 .59540 1.740 14 .104 
Pair 9 DyB - DyF .20000 .41404 .10690 -.02929 .42929 1.871 14 .082 
Table 18: Showing the Statistical Results of Group - B after 15 days follow-up Paired Sample Test 
Variables before 
and after treatment 
Paired Differences t Df Sig.(2 
tailed) Mean Std. 
Deviation 
Std. 
Error 
mean 
95% Confidence 
interval of Difference 
Lower Upper 
Pair 1  AgB - AgF .86667 .35187 .09085 .67181 1.06152 9.539 14 .000 
Pair 2  MaB - MaF 1.20000 .56061 .14475 .88954 1.51046 8.290 14 .000 
Pair 3 BaB - BaF .60000 .50709 .13093 .31918 .88082 4.583 14 .000 
Pair 4 GrB - GrF .26667 .45774 .11819 .01318 .52015 2.256 14 .041 
Pair 5 NiB - NiF .73333 .45774 .11819 .47985 .98682 6.205 14 .000 
Pair 6 SwB - SwF .46667 .51640 .13333 .18070 .75264 3.500 14 .004 
Pair 7 SKB - SKF 1.00000 .65465 .16903 .63746 1.36254 5.916 14 .000 
Pair 8 SyB - SyF .20000 .41404 .10690 -.02929 .42929 1.871 14 .082 
Pair 9 DyB - DyF .13333 .35187 .09085 -.06152 .32819 1.468 14 .164 
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Table 19: Showing the Statistical Results of Comparative Study Between Group - A and Group- B Paired Samples 
Test 
 Paired Differences T Df Sig. (2-
tailed) Mean Std. 
Deviation 
Std. Error 
Mean 
95% Confidence Interval 
of the Difference 
Lower Upper 
Pair 1 AgA - AgB .06667 .25820 .06667 -.07632 .20965 1.000 14 .334 
Pair 2 MaA - MaB .26667 .45774 .11819 .01318 .52015 2.256 14 .041 
Pair 3 BaA - BaB .06667 .25820 .06667 -.07632 .20965 1.000 14 .334 
Pair 4 GrA - GrB .06667 .59362 .15327 -.26207 .39540 .435 14 .670 
Pair 5 NiA - NiB .06667 .25820 .06667 -.07632 .20965 1.000 14 .334 
Pair 6 SwA - SwB .20000 .56061 .14475 -.11046 .51046 1.382 14 .189 
Pair 7 SKA - SKB .00000 .75593 .19518 -.41862 .41862 .000 14 1.000 
Pair 8 SyA - SyB -.06667 .45774 .11819 -.32015 .18682 -.564 14 .582 
Pair 10 WtA - WtB -.13333 2.99682 .77378 -1.79292 1.52625 -.172 14 .866 
Pair 11 HbA - HbB .13333 1.06010 .27372 -.45373 .72040 .487 14 .634 
NOTE - Ag - Agnimandhya, Ma - Malabaddhata, Ba -Balakshaya, Gr - Grahana kshaya, Ni- Nidra nasha,Sw - Shwasa, SK - 
Sarvakriya cha asamarthata, Sy- Systolic BP, Dy -Diastolic BP, Wt -Weight, Hg- Hemoglobin, B - Before treatment, A - After 
treatment. 
Bar Diagrams Show the Result of Group -A 
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Figure 2.0: Bar diagram showing the mean with standard deviation of the parameters of Group A (pair t test)
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Bar Diagram Show the Result of Group - B 
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parameters of Group B (pair t test)
Sc
or
e
 
 Int. J. Ayur. Pharma Research, 2016;4(8):1-11  
 IJAPR | August 2016 | Volume 4 | Issue 8  9 
DISCUSSION ON RESULTS 
Agnimandhya (Loss of appetite) 
 Person of both groups A and B had shown 
significant result in the treatment of Agnimandhya. Group 
A was having t value 12.475 AT and 4.583 at FU. Group B 
was having t value 11.225 AT and 9.539 at FU so the 
treatment of Group B may be better than the treatment of 
Group A. But after comparing the result between both 
Groups A and B the equal efficacy (p = <0.000) was 
observed on Agnimandhaya after treatment. 
Malabaddhata (Constipation) 
 In this parameter Persons of both groups had 
shown significant result (P= <0.000). The t values of Group 
A were 6.205AT and 3.055 FU. The t values of Group B 
were 8.264 AT and 8.290 FU so the comparative study 
between Group A and Group B had shown that the 
treatment modality of Group B was better than Group A. 
(p=0.041). 
Balakshaya (Loss of physical strength) 
 In the cases of Balakshaya 93.3% case from Group 
A and 100% cases from Group B shown clinically 
encouraging response after the treatment where 6.6% of 
cases were normal from Group A before the treatment. The 
p value of both groups A and B (<0.001) shown statically 
highly significance after the treatment so comparative 
study between both groups A and B indicates equal 
efficacy of both treatment modalities after the treatment. 
Grahana kshaya (Loss of grasping power) 
 In this study, from Group A, 80.3% persons had 
got clinically encouraging response and 20% persons had 
got clinically stable response. Similarly from Group B the 
6.6% persons had got clinically good response, clinically 
encouraging response had been seen in 73.3% persons and 
clinically stable seen in 6.6% persons. So both treatments 
modalities were capable for prevent the degeneration and 
strengthen the nervous system because statically the both 
treatment groups were highly significant. (p value - 
<0.001.2-tailed.000), but the post treatment follow up 
study showed t values of Group A and Group B were 1.871 
and 2.256 respectively, that indicates the treatment 
regimen of Group B was fast acting than Group A on 
Grahana-kshaya. 
Nidra nasha (Insomnia) 
 In this clinical study the both Groups A and B had 
shown that statically highly significant result (p=<0.001) 
after the treatment and had equal efficacy against the 
Nidranasha (sleeplessness). The two weeks post treatment 
follow up study showed t values of Group A and Group B 
were 4.583 and 6.205 respectively, that indicates the 
treatment regimen of Group B was fast acting than Group 
A on Nidranasha.  
Shwasa (Exertional dyspnea) 
 In this clinical study the both Groups A and B had 
shown that statically highly significant result (p=<0.001) 
after the treatment and had equal efficacy against the 
Shwasa (exertional dyspnoea), but the t values of two 
weeks post treatment follow up of Group A and Group B 
were 1.468 and 3.500 respectively that indicates the 
treatment regimen of Group B shows its efficacy in short 
duration of time than treatment regimen of Group A. 
Sarva kriya su cha asamarthata (Functional 
impairment) 
 The t values of Group A were 3.055 (AT) and 
1.468 (FU) and Group B were 9.025 (AT) and 5.916 (FU) 
that indicates the person of Group B had shown more 
Significant result than the person of Group A. 
Discussion on Objective Variables 
Blood pressure (Systolic) 
 Group A had shown significant result for systolic 
blood pressure as Group B had shown non significant 
result. The t value of Group A were 2.168 (AT) and Group B 
was having of t value 2.103 (AT). 
Blood pressure Diastolic 
 On this variable, Group A had shown significant 
result as Group B had shown no significant result. The t 
value of Group A and B were 2.256 (AT) and 1.871 (AT) 
respectively.  
Weight  
 Group B had shown significant results for this 
parameter where Group A had shown non significant 
statistically. But slight increase in weight was seen in 
persons of group A also. The t value for Group A and Group 
B were 1.871 AT and 2.256 AT respectively.  
Hemoglobin  
 The both Groups A and B had shown significant 
results. The t value for Group A was 2.824 AT and Group B 
was having 3.674 AT so that indicates the treatment 
regimen of Group B is better than Group A but when the 
results were compared in between Group A and Group B 
statistically, it was shown equal efficacy of both Groups. 
 The trial drugs of group A, Ashwagandha rasayana 
has shown highly significant result in treating symptoms 
like Agnimandhya, Malabadhata, Bala kshaya, Grahan 
kshaya, Swasa and Nidranash similarly significant 
responses seen in Sarvakriyasu cha asamarthata, Blood 
pressure and hemoglobin percentage. Hence Ashwagandha 
rasayana is an effective remedy for ageing process 
management. The trial drug of group B, Ashwagandha 
rasayana with Mahanarayan tail matra basti has shown 
highly significant result on symptoms like Agnimandhya, 
Malabadhata, Bala kshaya, Grahan kshaya, Swasa, 
Nidranash Sarva kriya asamarthata and Hemoglobin 
percentage and significant responses seen on Weight loss 
Hence Ashwagandha rasayana with Matra basti is very 
effective in treating ageing ailments. In comparison in 
between both Group A and B, the result was statistically 
insignificant but the good response percentages of Group B 
was high than Group A.  
Probable action of drugs 
Mode of action of Ashwagandha 
 Ashwagandha by virtue of its Rasa, Guna, Veerya, 
Vipaka and Prabhava, promotes, digestion, metabolism, 
maintains homeostasis of Doshas, enriches nourishment 
and promotes body and mental functions thus becomes 
effective in aging. Its Tikta, Katu – Rasa + Laghu – Guna + 
Ushna veerya and Vatashamaka karma promotes digestion 
and metabolism their by production of rasa and 
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elimination of toxic metabolites and pollutants is achieved. 
Due to its Snigdha guna + Ushna veerya + Madhurvipaka + 
Vataghana + Rasayan property - Vata dosha shamana 
occurs. Its Snigdha guna + Madhura vipaka (Snigdha 
+guru) + Rasayana + Balya + Vrushya – Dhatu and Bala 
vardhan are achieved. 
Correcting Vata + Rasayana (Prabhava) + Medhya property 
> Does Mano Prasannata 
Modern concept  
 Several types of alkaloids are found in the plant of 
which withenia, somnifera and withasomnine are 
important in traditional preparations. The alkaloid 
withaferin is responsible for the bacteriostatic and anti 
tumour properties. Recently steroidal factors have been 
isolated from leaves. The withanoloids are believed to 
account for the multiple applications of Ashwagandha. 
These molecules are steroidal and bear a resemblance, 
both in their action and appearance to the active 
constituents of Asian ginseng (panax ginseng) known as 
ginsenosides and are called as Indian ginseng. These serve 
as important hormones precursors, which the body is then 
able, as needed to convert into human physiological 
hormones. If there is an excess of certain hormones, the 
plant based hormones precursor occupied the so called 
hormone receptors sites without converting to human 
hormones to block absorption. In this way Ashwagandha 
like other adoptogenic tonic herbs is amphoteric and can 
serve to regulate important physiological processes, 
increasing or decreasing as needed. Generally 
Ashwagandha stimulates the immune system. It has also 
been shown to inhibit inflammation and improve memory. 
It counteracts the effects of stress and promotes wellness. 
Along with this, Ashwagandha improves the degenerative 
changes by effect on chondroplasts in cartilage as well as it 
creates hemopoetic effect by cyclophosphamide and 
reduces leukopenia[9]. 
Mode of action of Matra basti 
 Basti Chikitsa is the prime treatment modality of 
Ayurveda. It is also considered as Ardha Chikitsa (half 
treatment). Matra basti is one of Sneha or Anuvasana 
Basti (unctuous enema) which promotes Bala (strength) of 
the person who is emaciated and debilitated. About the 
possibility of the absorption of Basti Dravyas (drugs) from 
the colon, some are of the opinion that substances other 
than water, salt, etc., are not absorbed from the large gut; 
but this is physiological phenomenon occurring in day-to-
day life, while the colon mucosa under the effect of the 
medication can be rendered to absorb the unusual 
substance also from the large gut. Favoring this view 
modern medical science is suggestive of some of the 
nutrient enemas meant for the nutrition of the body, 
where absorption of carbohydrate, fat and protein is 
mentioned.[10] Observation of modern medical science that 
administration of sodium chloride improves fat 
absorption[10] is curiously coinciding with the usage of salt 
designed by Ayurvedic medical authorities in Sadyo-
Snehana[11] and in many Basti Dravya preparations along 
with the different Sneha Dravyas. Charaka narrates the role 
played by Lavana along with the Sneha by the words 
“Lavanopitaha Snehana Snehayantyachiratnaram.”[12] 
Charaka while assessing the Anuvasana Basti records the 
digestion of Sneha by the words “Sneham Pachati 
Pavakah”90 and after digestion Dravyas can be absorbed to 
cause the affect on the body.  
CONCLUSION 
 It is interesting to note that there is a shift in the 
population growth from child and young to higher age 
groups. 
 Due to increased elderly population, the prevalence of 
geriatric specific disease conditions is also increasing. 
Ayurveda is essentially science of life and longevity. It 
presents a sound concept of aging and its prevention 
and management. 
 The Jara vyadhi has been extensively explained in 
Ayurvedic classics, which can be correlated with 
geriatrics and Rasayana therapy acts as one of the 
useful remedy in promotion of the early ageing and 
prevention of ill effects of ageing. 
 Both the groups provided better results on the chief 
complaints But, comparison in between both the 
groups is insignificant, that may be due to small sample 
size. 
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